1. Home
  2. NCT vs COYA Comparison

NCT vs COYA Comparison

Compare NCT & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCT
  • COYA
  • Stock Information
  • Founded
  • NCT 2011
  • COYA 2020
  • Country
  • NCT Hong Kong
  • COYA United States
  • Employees
  • NCT N/A
  • COYA N/A
  • Industry
  • NCT
  • COYA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NCT
  • COYA Health Care
  • Exchange
  • NCT NYSE
  • COYA Nasdaq
  • Market Cap
  • NCT 114.7M
  • COYA 99.8M
  • IPO Year
  • NCT 2025
  • COYA 2022
  • Fundamental
  • Price
  • NCT $3.79
  • COYA $5.51
  • Analyst Decision
  • NCT
  • COYA Strong Buy
  • Analyst Count
  • NCT 0
  • COYA 4
  • Target Price
  • NCT N/A
  • COYA $17.00
  • AVG Volume (30 Days)
  • NCT 36.5K
  • COYA 41.5K
  • Earning Date
  • NCT 01-01-0001
  • COYA 08-11-2025
  • Dividend Yield
  • NCT N/A
  • COYA N/A
  • EPS Growth
  • NCT N/A
  • COYA N/A
  • EPS
  • NCT 0.13
  • COYA N/A
  • Revenue
  • NCT $25,526,936.00
  • COYA $3,685,107.00
  • Revenue This Year
  • NCT N/A
  • COYA $105.26
  • Revenue Next Year
  • NCT N/A
  • COYA N/A
  • P/E Ratio
  • NCT $30.96
  • COYA N/A
  • Revenue Growth
  • NCT N/A
  • COYA N/A
  • 52 Week Low
  • NCT $3.05
  • COYA $4.65
  • 52 Week High
  • NCT $8.76
  • COYA $10.24
  • Technical
  • Relative Strength Index (RSI)
  • NCT N/A
  • COYA 45.71
  • Support Level
  • NCT N/A
  • COYA $5.30
  • Resistance Level
  • NCT N/A
  • COYA $5.87
  • Average True Range (ATR)
  • NCT 0.00
  • COYA 0.38
  • MACD
  • NCT 0.00
  • COYA -0.01
  • Stochastic Oscillator
  • NCT 0.00
  • COYA 33.96

About NCT INTERCONT (CAYMAN) LIMITED

Intercont (Cayman) Ltd operates through its subsidiaries. It is principally engaged in the time charter service and vessel management services business.

About COYA Coya Therapeutics Inc.

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Share on Social Networks: